RHHBY Quote, Financials, Valuation and Earnings

Addex Therapeutics has a net margin of -- compared to Roche Holding AG's net margin of -2841.85%. Roche Holding AG's return on equity of 32.32% beat Addex Therapeutics's return on equity of 91.08%.

Roche Holding AG has a consensus price target of $47.55, signalling upside risk potential of 30.8%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 276.41%. Given that Addex Therapeutics has higher upside potential than Roche Holding AG, analysts believe Addex Therapeutics is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.409, which suggesting that the stock is 59.148% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Roche Holding AG has a quarterly dividend of $1.35 per share corresponding to a yield of 3.71%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 66.01% of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Addex Therapeutics quarterly revenues of $62.3K. Roche Holding AG's net income of -- is lower than Addex Therapeutics's net income of -$1.8M. Notably, Roche Holding AG's price-to-earnings ratio is 18.94x while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.45x versus 14.72x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CRISPR Therapeutics AG has a net margin of -- compared to Roche Holding AG's net margin of --. Roche Holding AG's return on equity of 32.32% beat CRISPR Therapeutics AG's return on equity of --.

Roche Holding AG has a consensus price target of $47.55, signalling upside risk potential of 30.8%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $84.08 which suggests that it could grow by 107.46%. Given that CRISPR Therapeutics AG has higher upside potential than Roche Holding AG, analysts believe CRISPR Therapeutics AG is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.409, which suggesting that the stock is 59.148% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.681, suggesting its more volatile than the S&P 500 by 68.115%.

Roche Holding AG has a quarterly dividend of $1.35 per share corresponding to a yield of 3.71%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 66.01% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of --. Roche Holding AG's net income of -- is lower than CRISPR Therapeutics AG's net income of -$85.9M. Notably, Roche Holding AG's price-to-earnings ratio is 18.94x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.45x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

NLS Pharmaceutics has a net margin of -- compared to Roche Holding AG's net margin of --. Roche Holding AG's return on equity of 32.32% beat NLS Pharmaceutics's return on equity of --.

Roche Holding AG has a consensus price target of $47.55, signalling upside risk potential of 30.8%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 12465.45%. Given that NLS Pharmaceutics has higher upside potential than Roche Holding AG, analysts believe NLS Pharmaceutics is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.409, which suggesting that the stock is 59.148% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Roche Holding AG has a quarterly dividend of $1.35 per share corresponding to a yield of 3.71%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 66.01% of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than NLS Pharmaceutics quarterly revenues of --. Roche Holding AG's net income of -- is lower than NLS Pharmaceutics's net income of --. Notably, Roche Holding AG's price-to-earnings ratio is 18.94x while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.45x versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -- compared to Roche Holding AG's net margin of 24.21%. Roche Holding AG's return on equity of 32.32% beat Novartis AG's return on equity of 41.89%.

Roche Holding AG has a consensus price target of $47.55, signalling upside risk potential of 30.8%. On the other hand Novartis AG has an analysts' consensus of $112.67 which suggests that it could grow by 15.52%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Roche Holding AG has a beta of 0.409, which suggesting that the stock is 59.148% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.571, suggesting its less volatile than the S&P 500 by 42.907%.

Roche Holding AG has a quarterly dividend of $1.35 per share corresponding to a yield of 3.71%. Novartis AG offers a yield of 3.83% to investors and pays a quarterly dividend of $3.74 per share. Roche Holding AG pays 66.01% of its earnings as a dividend. Novartis AG pays out 48.86% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.2B. Roche Holding AG's net income of -- is lower than Novartis AG's net income of $3.2B. Notably, Roche Holding AG's price-to-earnings ratio is 18.94x while Novartis AG's PE ratio is 11.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.45x versus 4.01x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.